News
Sartorius Stedim Biotech SA: Information on Document Availability
EQS-News: Abivax appoints Dr. Sheldon Sloan, M.D., as Chief Medical Officer
EQS-Adhoc: BB Biotech AG publishes its 2022 annual report
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 2, 2023, following the release of its fourth
Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it
Lysogene Announces the Extension of Deadline for the Submission of Offers
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that, upon decision of the judicial
Kuros Biosciences Announces Changes to Executive Management Team
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
Pfizer (NYSE: PFE) announced today positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI®
Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning Models
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced it has entered a new collaboration
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a multi-program agreement with Pioneering Medicines, a strategic initiative of Flagship Pioneering, that gives Pioneering
Newron Reports Striking One-Year Interim Efficacy Results From Its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients With Treatment-Resistant Schizophrenia
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults
Pfizer Inc. (NYSE: PFE) today announced publication of results in The Lancet Neurology from the Phase 3 pivotal clinical trial of zavegepant, an investigational calcitonin gene-related peptide
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
Cosmo Pharmaceuticals reports record results for 2022, preliminary results exceeding guidance, increased dividend distribution and 2023 guidance
Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration
Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a
QuidelOrtho Reports Fourth Quarter and Full Year 2022 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and
Poxel Reports Cash and Revenue for the Full Year 2022 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today provides a regulatory update on the clinical development plan of Tedopi®, an immunotherapy activating
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the pivotal PANOVA-3 study evaluating the efficacy of Tumor Treating Fields (TTFields) together with
QIAGEN erhält CE-Kennzeichnung für Tuberkulose-Bluttest QuantiFERON-TB Gold Plus nach EU-Verordnung über In-vitro-Diagnostika (IVDR)
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Zertifizierung von QuantiFERON-TB Gold Plus (QFT-Plus) – dem weltweit führenden Tuberkulose-Bluttest – gemäß der EU-Verordnung
QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the certification of QuantiFERON-TB Gold Plus (QFT-Plus) – the world’s leading tuberculosis (TB) blood test – under the
EQS-News: Abivax to present blood and rectal tissue data from UC patients treated with obefazimod at the 18th Congress of ECCO
Premier’s PINC AI™ Receives 2023 Best in KLAS Award for Value-Based Care Consulting
PINC AI™, the technology and services platform of Premier Inc. (NASDAQ: PINC), a leading healthcare improvement and technology company, has been awarded the 2023 Best in KLAS designation for
Savara Announces New Leadership Appointments
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointments of two pharmaceutical industry veterans to its